The companies clash over survival curve similarities – and differences.
ApexOnco Front Page
Recent articles
Petosemtamab's phase 2 data in this setting should come by the year end.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
